Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

In June 2025, COMPASS Pathways shared data from the Phase 3 COMP005 trial. A single dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom ...

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...

Gain an autonomous research partner that reveals insights, launches studies, and formulates winning strategies - ...

COMPASS GOES HAYWIRE: It’s déjà vu at the California Energy Commission. Another major renewable energy project that applied for the state’s special fast-track permitting process is on hold. The CEC ...

FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--MDT, a CUSO that helps credit unions navigate complex financial technology ecosystems, today announced the launch of its MDT Compass App, a cloud-based ...